CN101715437B - 立体异构异丙酚治疗性化合物 - Google Patents

立体异构异丙酚治疗性化合物 Download PDF

Info

Publication number
CN101715437B
CN101715437B CN2008800153921A CN200880015392A CN101715437B CN 101715437 B CN101715437 B CN 101715437B CN 2008800153921 A CN2008800153921 A CN 2008800153921A CN 200880015392 A CN200880015392 A CN 200880015392A CN 101715437 B CN101715437 B CN 101715437B
Authority
CN
China
Prior art keywords
compound
propofol
formula
sec
butylphenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800153921A
Other languages
English (en)
Chinese (zh)
Other versions
CN101715437A (zh
Inventor
T·E·詹金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wood Medical Ltd
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of CN101715437A publication Critical patent/CN101715437A/zh
Application granted granted Critical
Publication of CN101715437B publication Critical patent/CN101715437B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06—Alkylated phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C07C37/0555—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2008800153921A 2007-05-09 2008-05-08 立体异构异丙酚治疗性化合物 Expired - Fee Related CN101715437B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92832707P 2007-05-09 2007-05-09
US92842907P 2007-05-09 2007-05-09
US92829607P 2007-05-09 2007-05-09
US60/928,327 2007-05-09
US60/928,296 2007-05-09
US60/928,429 2007-05-09
PCT/US2008/063082 WO2008141097A2 (en) 2007-05-09 2008-05-08 Stereoisomers propofol therapeutic compounds

Publications (2)

Publication Number Publication Date
CN101715437A CN101715437A (zh) 2010-05-26
CN101715437B true CN101715437B (zh) 2013-06-12

Family

ID=39798084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800153921A Expired - Fee Related CN101715437B (zh) 2007-05-09 2008-05-08 立体异构异丙酚治疗性化合物

Country Status (22)

Country Link
US (4) US8071818B2 (enExample)
EP (4) EP2810927A1 (enExample)
JP (1) JP5651009B2 (enExample)
KR (1) KR20100017436A (enExample)
CN (1) CN101715437B (enExample)
AT (1) ATE487685T1 (enExample)
AU (1) AU2008251482C1 (enExample)
BR (1) BRPI0811220A2 (enExample)
CA (1) CA2685570A1 (enExample)
DE (1) DE602008003431D1 (enExample)
DK (2) DK2146946T3 (enExample)
ES (1) ES2501592T3 (enExample)
HR (1) HRP20140896T1 (enExample)
IL (1) IL201795A0 (enExample)
MX (1) MX2009012124A (enExample)
NZ (1) NZ580752A (enExample)
PL (2) PL2146946T3 (enExample)
PT (1) PT2146946E (enExample)
RU (1) RU2470908C2 (enExample)
SI (1) SI2301908T1 (enExample)
WO (1) WO2008141097A2 (enExample)
ZA (1) ZA201007603B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2146946T3 (pl) 2007-05-09 2011-04-29 Pharmacofore Inc (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi
WO2012017950A1 (ja) * 2010-08-03 2012-02-09 学校法人 久留米大学 実験用小動物の脳波測定用電極装置及び脳波測定方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
US11331271B2 (en) * 2016-05-27 2022-05-17 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
RU2635532C1 (ru) * 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN115708819A (zh) * 2022-11-24 2023-02-24 中国科学院深圳先进技术研究院 丙泊酚的抗焦虑制药用途及抗焦虑药物制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US237213A (en) 1881-02-01 William j
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731356A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
AU3000800A (en) 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
BR0215303A (pt) 2001-12-28 2005-04-05 Guilford Pharm Inc Formulações farmacêuticas de base aquosa de pró-drogas solúveis em água de propofol
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
KR20070087004A (ko) 2002-04-08 2007-08-27 엠쥐아이 쥐피, 아이엔씨. 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005023204A2 (en) 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
WO2005033279A2 (en) * 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
US7241807B2 (en) 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
WO2006033911A2 (en) 2004-09-17 2006-03-30 Mgi Gp, Inc. Methods of administering water-soluble prodrugs of propofol
ATE456552T1 (de) 2004-12-23 2010-02-15 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
EP1965780B1 (en) 2005-12-19 2017-03-08 The University Of Liverpool Propofol derivatives as analgesics
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) * 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses
CA2685813A1 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
PL2146946T3 (pl) 2007-05-09 2011-04-29 Pharmacofore Inc (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRASOWSKI MATTHEW D ET AL.genetal anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (gaba) current at the gaba receptor but not with lipid solubility.《JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERRIMENTAL THERAPEUTICS》.2001,第297卷(第1期),338-351. *

Also Published As

Publication number Publication date
EP2301908B8 (en) 2014-09-03
US8071818B2 (en) 2011-12-06
EP2301908B1 (en) 2014-06-25
ZA201007603B (en) 2012-08-29
US20130059919A1 (en) 2013-03-07
CA2685570A1 (en) 2008-11-20
PL2301908T3 (pl) 2015-02-27
HK1138829A1 (en) 2010-09-03
DK2146946T3 (da) 2011-02-14
PL2146946T3 (pl) 2011-04-29
US20140206773A1 (en) 2014-07-24
EP2810927A1 (en) 2014-12-10
AU2008251482A1 (en) 2008-11-20
DK2301908T3 (da) 2014-09-15
JP5651009B2 (ja) 2015-01-07
AU2008251482B2 (en) 2013-09-26
KR20100017436A (ko) 2010-02-16
CN101715437A (zh) 2010-05-26
NZ580752A (en) 2012-03-30
EP2146946A2 (en) 2010-01-27
HK1156019A1 (en) 2012-06-01
IL201795A0 (en) 2010-06-16
BRPI0811220A2 (pt) 2014-10-29
RU2009145537A (ru) 2011-06-20
EP2301908A1 (en) 2011-03-30
PT2146946E (pt) 2011-02-14
WO2008141097A9 (en) 2009-04-02
WO2008141097A3 (en) 2008-12-31
US20100292346A1 (en) 2010-11-18
AU2008251482C1 (en) 2014-04-03
US8242315B2 (en) 2012-08-14
ATE487685T1 (de) 2010-11-15
US8871815B2 (en) 2014-10-28
US8575400B2 (en) 2013-11-05
SI2301908T1 (sl) 2014-10-30
JP2010526826A (ja) 2010-08-05
HRP20140896T1 (hr) 2015-01-02
EP2146946B1 (en) 2010-11-10
MX2009012124A (es) 2010-02-18
RU2470908C2 (ru) 2012-12-27
ES2501592T3 (es) 2014-10-02
DE602008003431D1 (de) 2010-12-23
EP2292577A1 (en) 2011-03-09
US20120035271A1 (en) 2012-02-09
WO2008141097A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
US8173849B2 (en) Therapeutic compounds
CN101715437B (zh) 立体异构异丙酚治疗性化合物
ES2354595T3 (es) (-)-estereoisómero de 2,6-di-sec-butilfenol y análogos del mismo.
HK1156019B (en) (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect, treatment of nausea and vomiting and treatment of migraine
HK1138829B (en) (-)- stereoisomer of 2,6-di-sec-butylphenol and analogs thereof
HK1155433A (en) (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof
HK1138830B (en) Therapeutic compounds
NZ580759A (en) Stereoisomers propofol therapeutic compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Delaware

Applicant after: Signature Therapeutics Inc

Address before: American California

Applicant before: Pharmacofore Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: PHARMACOFORE INC. TO: SIGNATURE THERAPEUTICS INC.

GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SOWOOD MEDICAL CORP.

Free format text: FORMER OWNER: SIGNATURE THERAPEUTICS INC.

Effective date: 20150217

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150217

Address after: Massachusetts, USA

Patentee after: Wood Medical Ltd

Address before: Delaware

Patentee before: Signature Therapeutics Inc

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130612

Termination date: 20150508

EXPY Termination of patent right or utility model